Maurie Markman

University of Texas M.D. Anderson Cancer Center, United States of America

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Oncology > Gynecological Cancers (since 26 February 2008)

Links

http://www.mdanderson.org/Care_Centers/Gyn/display.cfm?id=0e763fdf-ffbb-4350-ac80bcee2331ee79&method=displayfull&pn=cb797b39-7868-11d4-aec400508bdcce3a

All recent recommendations

• 3.0
  Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
  Recommended by Maurie Markman
  
• 3.0
  Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
  Recommended by Maurie Markman
  
• 3.0
  Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
  Recommended by Maurie Markman
  
• 3.2
  For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
  Recommended by Paola Gehrig, Maurie Markman
  
• 3.0
  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
  Recommended by Maurie Markman
  
• 3.0
  Diagnostic markers for early detection of ovarian cancer.
  Recommended by Maurie Markman